Can Carboplatin Be Safely Omitted in Neoadjuvant HER2-Positive Breast Cancer? Evidence, Patient Selection, and Practice Impact
Reconsidering carboplatin in neoadjuvant HER2-positive breast cancer may reduce toxicity and resource use while maintaining outcomes, emphasizing individualized treatment decisions, patient experience, and careful monitoring.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.